As for the pharmacoeconomic evidence, on one hand, to date, there are a few existing comparative cost-effectiveness studies for the cost-effectiveness of palbociclib and ribociclib in stage IV HR+/HER2-negative breast cancer patients [17,18,19,20,21]. The gene discussed is ERBB2; the disease is breast cancer.